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Abstract
The use of oral contraceptives (OCs) by female athletes may lead to improved iron 
status, possibly through the regulation of hepcidin by sex hormones. The present 
work investigates the response of hepcidin and interleukin-6 (IL-6) to an interval 
exercise in both phases of the OC cycle. Sixteen endurance-trained OC users (age 
25.3 ± 4.7 years; height 162.4 ± 5.7 cm; body mass 56.0 ± 5.7 kg; body fat percent-
age 24.8 ± 6.0%; peak oxygen consumption [VO2peak]: 47.4 ± 5.5 mL min
−1 kg−1) 
followed an identical interval running protocol during the withdrawal and active pill 
phases of the OC cycle. This protocol consisted of 8 × 3 minutes bouts at 85% VO2peak 
speed with 90 seconds recovery intervals. Blood samples were collected pre-exer-
cise, and at 0 hour, 3 hours, and 24 hours post-exercise. Pre-exercise 17β-estradiol 
was lower (P = .001) during the active pill than the withdrawal phase (7.91 ± 1.81 
vs 29.36 ± 6.45 pg/mL [mean ± SEM]). No differences were seen between the OC 
phases with respect to hepcidin or IL-6 concentrations, whether taking all time points 
together or separately. However, within the withdrawal phase, hepcidin concentra-
tions were higher at 3 hours post-exercise (3.33 ± 0.95 nmol/L) than at pre-exer-
cise (1.04 ± 0.20 nmol/L; P = .005) and 0 hour post-exercise (1.41 ± 0.38 nmol/L; 
P = .045). Within both OC phases, IL-6 was higher at 0 hour post-exercise than at 
any other time point (P < .05). Similar trends in hepcidin and IL-6 concentrations 
were seen at the different time points during both OC phases. OC use led to low 
17β-estradiol concentrations during the active pill phase but did not affect hepcidin. 
This does not, however, rule out estradiol affecting hepcidin levels.
K E Y W O R D S
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1 |  INTRODUCTION
Oral contraceptives (OCs) are used worldwide. Nearly 70% 
of female athletes use hormonal contraception during their 
reproductive life, with 68.1% of them using OCs.1 Oral con-
traceptive formulations have changed over time, with later 
generations containing much lower doses of sex hormones. 
Monophasic OCs, which contain a set amount of estradiol 
and progestin in each pill, are the most commonly used.2 
Certainly, they are frequently employed by female athletes to 
control their menstrual cycles, reduce menstrual symptoms, 
and shorten menstruation, and even to improve their iron sta-
tus.3 By reducing menstrual bleeding, ferritin —the primary 
form of stored iron in cells— and iron concentrations may be 
enhanced in OC users compared to women with eumenor-
rheic cycles.4
Iron homeostasis is regulated by hepcidin, an antimicro-
bial peptide synthesized in the liver. Hepcidin binds, inter-
nalizes, and degrades ferroportin, the cellular iron exporter, 
blocking the absorption of dietary iron into the circulation, 
and inhibiting iron recycling macrophages and the release of 
body iron stores.5 Estradiol and progesterone may influence 
hepcidin regulation. Estradiol has been reported to inhibit 
hepcidin,6-8 potentially via an estrogen-responsive element 
in the hepcidin promoter.6,7 In contrast, Ikeda et al9 reported 
hepcidin to be upregulated by estradiol through the induction 
of bone morphogenetic protein-6, one of the main activators 
of the major hepcidin production pathway (BMP-SMAD).5 
Progesterone has been proposed to induce hepcidin produc-
tion via progesterone receptor membrane component-1.10 
However, the above studies were all performed in animals 
or in women under in vitro fertilization treatment and did not 
take into account eumenorrheic or OC-influenced cycles. 
Further study is therefore needed to clarify these hormones' 
roles in hepcidin regulation.
Regular exercise, especially endurance training, has been 
associated with iron deficiency and iron deficiency anemia.11 
Exercise is also known to increase inflammation-responsive 
cytokine levels, especially that of interleukin-6 (IL-6),12 a 
major regulator of hepcidin expression.5 Time-course hep-
cidin and IL-6 response studies report peak serum hepci-
din concentrations around 3 hours after serum IL-6 reaches 
a peak (usually immediately after exercise).12,13 One study 
has examined the response of hepcidin to running exercise 
during the active pill and withdrawal phases of monophasic 
OC-induced cycles,14 with no changes in hepcidin or IL-6 
reported between these phases. However, sex hormone con-
centrations were not measured in that study, precluding obser-
vations being made on the interaction between sex hormones 
and hepcidin. This would be of interest since OCs have been 
shown to reduce endogenous estradiol concentrations during 
the active pill phase.15 With the hypothesis that the response 
of hepcidin to exercise may be stronger during this phase, the 
present study investigates the hepcidin and IL-6 responses to 
interval running exercise in relation to the estradiol and pro-
gesterone profiles of women using monophasic OCs.
2 |  MATERIALS AND METHODS
2.1 | Study subjects
The study subjects were 16 healthy endurance-trained fe-
male athletes taking monophasic OCs (age 25.3 ± 4.7 years; 
height 162.4 ± 5.7 cm; body mass 56.0 ± 5.7 kg; percentage 
body fat 24.8 ± 6.0%; peak oxygen consumption [VO2peak] 
47.4  ±  5.5  mL·min−1·kg−1). All subjects took their active 
hormone pill at the same time each day for 21 days (active 
pill phase), followed by a 7-day withdrawal (non-active pill) 
phase. All subjects had used OCs for the last 4.1 ± 4.3 years 
and had practiced endurance training for 5.8  ±  5.0  years, 
which involved 215 ± 170 min/wk over the six months prior 
to recruitment.
The inclusion criteria required all subjects to the follow-
ing: (a) be female, healthy and between 18 and 40 years of age; 
(b) use monophasic OCs for a minimum of six months prior 
to the start of the study; (c) undertake endurance training be-
tween 3 and 12 hours per week; (d) be free of iron deficiency 
anemia (serum ferritin < 20 μg/L, hemoglobin < 115 g/L, 
and transferrin saturation < 16%); (e) have healthy thyroid 
function; (f) be a non-smoker; (g) be taking no medication 
other than the OC, nor any dietary supplement (including any 
iron supplementation); (h) not be pregnant; and (i) have not 
undergone ovariectomy. To verify these conditions were met, 
all potential subjects completed a questionnaire and under-
went blood analyses prior to acceptance.
Twenty-nine subjects were initially enrolled, but an unex-
pected drop out rate (scheduling problems 6; afraid of nee-
dles 2; low performance in the maximal test [VO2peak below 
the 50th percentile for the general population for age group16] 
2; inability to obtain blood samples 1; menstrual bleeding 
during active pill phase 1; unable to complete the exercise 
protocol 1) reduced the final figure to 16.
This study was approved by the Institutional Review 
Board of the Research Ethics Committee of the Universidad 
Politécnica de Madrid. Subjects were informed of the risks 
and benefits of the study before participation, and each 
signed an institutionally approved document of informed 
consent. This trial was registered at clinicaltrials.gov (ID: 
NCT04458662).
2.2 | Oral contraceptives
The subjects used different monophasic OC preparations 
during the study, providing different doses of exogenous 
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hormones that ranged from 0.075 to 250 mg of progestogen 
and from 0.02 to 35 mg of ethinylestradiol (Table S1). All 
presentations included seven days worth of placebo pills with 
no hormonal load, corresponding to the withdrawal phase (ie, 
days 1-7 of the cycle), and 21 days worth of exogenous hor-
mone pills corresponding to the active pill phase (ie, days 
8-28 of the cycle).
2.3 | Study design
All subjects visited the laboratory on three occasions over 
two complete OC cycles (28 days per cycle). In the first ses-
sion, they were subjected to a baseline analysis (see below) 
during the withdrawal phase (days 3-7 of the cycle). They 
then performed an interval running protocol under labo-
ratory-controlled conditions, once during the withdrawal 
phase (day 4.9  ±  1.8, ie, “late withdrawal” to catch peak 
ovarian activity) and once during the active pill phase (day 
22.1 ± 5.0, ie, “late pill consumption” to catch downregulat-
ing ovarian activity and increased circulation of exogenous 
hormone concentrations). Previous research has shown that 
in combined monophasic OCs, serum ethynyl estradiol con-
centrations triple with OC intake over day 1-21 of the ac-
tive pill phase.17,18 Similarly, serum progestin concentrations 
quadruple, reaching a steady concentration after 8-11 days of 
daily OC consumption.17,18 The interval running tests were 
conducted at the same time of day to minimize any effect of 
diurnal rhythm. To reduce the influence of any learning ef-
fect among the subjects, half underwent examination of the 
withdrawal phase first, while the other half underwent exami-
nation of the active pill phase first.
2.4 | Baseline analyses
Resting blood samples were taken following an overnight 
fast and before any morning food intake. A complete blood 
count and biochemical and hormone analyses were per-
formed to verify that none of the participants showed signs 
of inflammation, iron deficiency, or thyroid problems. A 
dual-energy x-ray absorptiometry (DXA) scan was then per-
formed to assess body composition including body fat mass 
(%), total body fat mass (kg), and fat-free mass (kg); this was 
done using a GE Lunar Prodigy apparatus (GE Healthcare). 
Finally, after eating and resting for a minimum of 2 hours, all 
subjects performed a maximal incremental test to exhaustion 
on an H/P/COSMOS 3PW 4.0 computerized treadmill (H/P/
Cosmos Sports & Medical GmbH, Nussdorf-Traunstein, 
Germany) to measure VO2peak. They began with a warm-
up of 3 minutes at 6 km/h, thereafter increased by 0.2 km/h 
every 12  seconds. A slope of 1% was maintained through-
out the test. Expired gases were measured breath-by-breath 
using a Jaeger Oxycon Pro gas analyzer (Erich Jaeger, Viasys 
Healthcare). Heart response was continuously monitored 
using a 12-lead ECG. The VO2peak was determined as the 
mean of the three highest VO2 measurements recorded in the 
incremental test to exhaustion. The maximal aerobic speed 
(vVO2peak) was recorded as the minimum speed required to 
elicit the VO2peak.
2.5 | Interval running protocol
Participants attended the laboratory between 08.00-
10.00 hour on test days to avoid the diurnal variability of hep-
cidin.19 Nutritional recommendations were provided to all 
subjects by a nutritionist in order to avoid the intake of pro-
inflammatory foods; these recommendations were followed 
by all subjects from 48  hours before the exercise protocol 
to 24  hours after competing it. They ate breakfast 2  hours 
before the test and were instructed to abstain from alcohol, 
caffeine, and exercise for the prior 24  hours. All subjects 
ate the same breakfast before testing during both OC cycle 
phases. Weight and blood pressure were recorded, and blood 
samples were collected to analyze sex hormones and iron ho-
meostasis variables. All subjects then performed the interval 
running exercise, which consisted of a 5 minutes warm-up 
at 60% vVO2peak followed by 8 bouts of 3 minutes at 85% 
vVO2peak with 90 seconds recovery at 30% vVO2peak between 
bouts, followed by a final 5  minutes cooling down period 
at 30% vVO2peak. This protocol was previously reported by 
Sim et al20 to stimulate a hepcidin response at 3 hours post-
exercise. Antecubital venous blood samples were collected 
at 0 hour, 3 hours, and 24 hours after finishing the exercise 
protocol.
2.6 | Blood collection
All venous blood samples were obtained using a 21-gauge 
(0.8  mm  ×  19  mm, Terumo®) needle. Blood samples for 
complete blood counts were collected in a 3 mL K3E EDTA 
K3 tubes (Vacuette®) and immediately sent to the clinical 
laboratory of the Spanish National Centre of Sport Medicine 
(Madrid, Spain) for analysis. Blood samples for serum varia-
bles were collected in a 9 mL Z serum separator clot activator 
tubes (Vacuette®) and allowed to clot at room temperature 
for 60 minutes. They were then centrifuged for 10 minutes at 
1610 g to obtain the serum (supernatant), divided into 600 µL 
aliquots, and stored at −80°C. When data collection was 
complete, serum samples were sent to the Spanish National 
Centre of Sport Medicine (Madrid, Spain) for IL-6, tumor 
necrosis factor alpha (TNF-α), iron, ferritin, transferrin, 
and C-reactive protein (CRP) analyses. Pre-exercise serum 
samples were also analyzed for 17β-estradiol, progesterone, 
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luteinizing hormone (LH), and follicle-stimulating hormone 
(FSH). Duplicate serum samples were sent to the Department 
of Laboratory Medicine at Radboud University Medical 
Centre (Hepcidinanalysis.com, Nijmegen, The Netherlands) 
for hepcidin-25 analysis.
2.7 | Blood analysis
Samples were allowed to defrost at room temperature and 
homogenized in a vortex. Serum iron content was determined 
using colorimetry in the visible range, while ferritin, trans-
ferrin, and CRP were analyzed by turbidimetry. Both col-
orimetry and turbidimetry were conducted using an AU400 
clinical analyzer (Beckman Coulter) with Beckman Coulter 
reagents. IL-6, 17β-estradiol, progesterone, FSH, and LH 
were determined by electrochemiluminescent immunoassay 
using Roche Diagnostics reagents in a Cobas E411 analyzer 
(Roche Diagnostics GmbH). TNF-α was determined using 
the IMMULITE® 1000 Immunoassay System (Siemens 
Healthineers, Malvern). Standard control samples were 
measured after calibration and after each analysis batch to 
ensure the continued accuracy of the results. Table S2 shows 
the inter- and intra-assay coefficients of variation (CV) for 
each variable.
Serum hepcidin was determined using a combination of 
weak cation exchange chromatography and time-of-flight 
mass spectrometry (WCX-TOF MS) using a stable hepci-
din-25+40 isotope (a secondary reference material21 as in-
ternal standard for quantification).22 Peptide spectra were 
generated using a Microflex LT matrix-enhanced laser de-
sorption/ionization TOF MS platform (Bruker Daltonics). 
Hepcidin-25 concentrations were expressed in nmol/L [nM]. 
The lower limit of quantification using this method was 0.5 
nM. Inter-assay CVs for hepcidin were 4.6% at the 11.0 nM 
level and 8.3% at the 2.7 nM level. Reference values can be 
found at http://www.hepci dinan alysis.com/provi ded-servi 
ce/refer ence-values (accessed 22 April 2020). Reference 
levels for the WCX-TOF MS method are recalculated from 
those of our ELISA method,22 based on the regression line: 
(ELISA−1.00)/1.52 = WCX-TOF MS that was derived from 
the results obtained by both methods for the same samples 
without hepcidin isoforms. All values were determined using 
secondary reference material for hepcidin assays, the value 
of which was assigned relative to the primary reference ma-
terial, allowing traceability to the internationally recognized 
Système International.21
2.8 | Statistical analysis
Data are expressed as the mean ± standard error of the mean 
(±SEM). The Shapiro-Wilk test was used to assess the 
normality of the variables. The non-parametric Friedman 
ANOVA test was used to analyze differences between time 
points (pre-exercise, 0 hour post-exercise, 3 hours post-ex-
ercise, and 24  hours post-exercise). The Wilcoxon signed-
rank test was used to compare differences in hepcidin, IL-6, 
TNF-α, ferritin, iron, transferrin, and CRP concentrations 
between the withdrawal phase and the active pill phase. The 
same test was used to measure differences between OC cycle 
phases in terms of 17β-estradiol, progesterone, LH, and FSH 
concentrations. Effect sizes (r) were calculated and set to 
small (≥0.1 and <0.3), moderate (≥0.3 and <0.5), and large 
( ≥0.5).23 Significance was set at P <  .05. All calculations 
were made using SPSS software v.25 (IBM Corp.,).
3 |  RESULTS
As expected, sex hormone concentrations (17β-estradiol, LH, 
and FSH) were significantly lower (Table 1 for P and r val-
ues) during the active pill phase of the OC cycle compared 




phase z P r
17 β-Estradiol 
(pg/mL)
29.36 ± 6.45 7.91 ± 1.81* −3.180 .001 −.56
Progesterone (ng/
mL)
0.33 ± 0.05 0.32 ± 0.03 −0.465 .642 −.08
LH (mIU/mL) 4.17 ± 1.14 1.79 ± 0.70* −2.981 .03 −.53
FSH (mIU/mL) 5.22 ± 1.05 1.51 ± 0.42* −3.233 <.001 −.57
Prolactin 
(mIU/L)
418.68 ± 54.35 501.09 ± 94.57 −1.241 .215 −.22
TSH (μIU/mL) 2.63 ± 0.29 2.96 ± 0.35 −1.526 .127 −.27
Note: Abbreviations: FSH, follicle-stimulating hormone; LH, luteinizing hormone; TSH, thyroid-stimulating 
hormone.
*Significantly different from withdrawal phase. 
T A B L E  1  Resting serum 
concentrations of hormones related to the 
oral contraceptive cycle (mean ± SEM)
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No significant differences were seen in hepcidin, IL-6, 
CRP, or ferritin between the OC phases, although hep-
cidin and CRP showed a trend toward being higher in the 
withdrawal and active pill phase respectively. In contrast, 
significant differences were detected for TNF-α, iron, and 
transferrin, the former two being higher and the last being 
lower during the active phase (Table 2 for P and r values).
No significant differences were seen between the OC phases 
at each time point (baseline, 0 hour, 3 hours, and 24 hours 
post-exercise) for hepcidin (Figure  1A), IL-6 (Figure  1B), 
CRP (Figure 1D) or ferritin (Figure 2B). However, the hep-
cidin concentration showed a trend toward being higher in 
the baseline samples of the withdrawal phase (z = −1.863; 
P = .063, r = −.33). Baseline TNF-α concentrations were sig-
nificantly higher during the active phase than the withdrawal 
phase (z = −2.312; P = .021, r = −.41) (Figure 1C), a dif-
ference that approached significance 3 hours after exercise as 
well (z = −1.915; P = .056, r = −.34). Serum iron was higher 
at all time points during the active pill phase than during 
the withdrawal phase: pre-exercise (z = −2.223; P =  .026, 
r = −.39), 0 hour (z = −1.965; P = .049, r = −.35), 3 hours 
(z = −1.862; P = .063, r = −.33) and 24 hours post-exercise 
(z = −2.442; P = .015, r = −.43) (Figure 2A). In contrast, 
transferrin concentrations were significantly lower during 
the active pill phase than the withdrawal phase at pre-exer-
cise (z = −2.172; P = .03, r = −.38), 0 hour (z = −2.690; 
P = .007, r = −.48), and at 3 hours (z = −2.121; P = .034, 
r = −.38) and 24 hours post-exercise (z = −2.386; P = .017, 
r = −.42) (Figure 2C).
Taking the results for the two phases together, hepcidin 
(χ2 = 35.500; P < .001), interleukin-6 (χ2 = 66.675; P < .001), 
TNF-α (χ2 = 13.641; P = .003), CRP (χ2 = 9.391; P = .025), 
iron (χ2  =  10.837, P  =  .013), transferrin (χ2  =  23.530, 
P < .001), and ferritin (χ2 = 21.059, P < .001) showed sig-
nificant increases at different times over the study period, re-
vealing an effect of time of measurement. Table S3 shows the 
results of pairwise comparisons.
The time of measurement also influenced the hepcidin 
result (Figure 1A) during both the withdrawal (χ2 = 20.333, 
P  <  .001) and active pill phases (χ2  =  15.370, P  =  .02). 
However, post-hoc pairwise comparisons showed the 
hepcidin concentration to be significantly higher at 
only 3  hours post-exercise compared with pre-exercise 
(P =  .005, r = −.59) and 0 hour post-exercise (P =  .045, 
r  =  −.47) during the withdrawal phase. In the active pill 
phase, a trend toward a higher hepcidin concentration was 
seen at 3  hours post-exercise compared with pre-exercise 
(P  =  .068). IL-6 showed the same pattern in both phases 
(withdrawal: χ2 = 31.879, P < .001; active pill: χ2 = 34.971, 
P < .001, Figure 1B), with higher concentrations at 0 hour 
post-exercise than at pre-exercise (withdrawal: P  =  .001, 
r = −.65; active pill: P =  .002, r = −.64), 3 hours (with-
drawal: P = .003, r = .62; active pill: P = .001, r = 0.67), 
and 24 hours post-exercise (withdrawal: P < .001, r = .71; 
active pill: P < .001, r = −.73), as did ferritin (withdrawal: 
χ2 = 9.444, P =  .024; active pill: χ2 = 12.333, P =  .006, 
Figure 2B), with higher concentrations at 0 hour post-exer-
cise than pre-exercise (withdrawal: P = .022, r = −.51; active 
pill: P = .010, r = −.56). Only during the withdrawal phase 
did TNF-α concentrations show significant differences over 
the time-course (χ2 = 12.402, P = .006; Figure 1C), being 
higher at 0 hour post-exercise compared with pre-exercise 
(P = .016, r = −.53). In contrast, transferrin concentrations 
were significantly different only in the active pill phase 
(χ2 = 23.058, P < .001; Figure 2C), being higher at 0 hour 
post-exercise than at pre-exercise (P = .002, r = −.63) and 
24 hour post-exercise (P <  .001, r =  .76). No differences 
were seen in CRP or iron concentrations between any time 
points (Figures 1D and 2A, respectively) in either the with-
drawal or active pill phase.
4 |  DISCUSSION
The present results show that low 17β-estradiol concentra-
tions induced by OCs likely explain the previously reported14 
lack of difference between the phases of the OC cycle in 




phase z P r
Hepcidin (nM) 1.76 ± 0.56 1.39 ± 0.44 −1.886 .059 −.17
Interleukin-6 (pg/mL) 2.13 ± 0.26 2.10 ± 0.26 −0.551 .581 −.05
TNF-⍺ (pg/mL) 5.12 ± 0.42 7.08 ± 0.86* −3.339 .001 −.3
CRP (mg/L) 1.48 ± 0.34 2.01 ± 0.37 −1.770 .077 −.16
Iron (µg/dL) 105.68 ± 11.09 131.54 ± 10.29* −4.094 <.001 −.36
Ferritin (ng/mL) 28.15 ± 3.33 28.13 ± 3.39 −0.212 .832 −.02
Transferrin (mg/mL) 346.33 ± 13.20 328.17 ± 11.94* −4.516 <.001 −.4
Note: Abbreviations: CRP, C-reactive protein; TNF-⍺, tumor necrosis factor alpha.
*Significantly different from withdrawal phase. 
T A B L E  2  Iron physiology and 
inflammation variables in each oral 
contraceptive cycle phase (mean ± SEM)
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observation previously proposed due to estradiol having no 
effect on hepcidin concentrations in humans.
The present hormone analysis results confirm that the 
subjects' OC consumption was adequate; endogenous estra-
diol and progestogen synthesis were therefore suppressed. 
The hepcidin concentrations showed a trend toward lower 
concentrations during the active pill phase. Higher hepcidin 
concentrations were observed during the withdrawal phase 
when estradiol was higher than during the active pill phase. 
In support of this, Ikeda et al9 reported ovariectomized mice 
to show lower hepcidin concentrations than sham-operated 
littermates. Interestingly, hepcidin concentrations in the ova-
riectomized mice were restored after estradiol supplementa-
tion. However, results from in vivo studies in mice6,7 and on 
human liver cells6 indicate that 17β-estradiol treatment in-
hibits hepcidin mRNA expression. Lehtihet et al8 found that 
gonadotropin-stimulated endogenous estradiol noticeably re-
duced circulating hepcidin in women receiving treatment for 
in vitro fertilization. However, the estradiol concentrations in 
the women of the latter study were approximately 130 times 
the highest concentrations found in the present subjects, and 
20 times those commonly seen in a natural menstrual cycle.
Earlier studies on human OC users reported no differences 
between OC phases for either hepcidin or IL-6, either when 
at rest14,24 or after performing a running exercise.14 While the 
present results are in agreement with this, the latter authors' 
arguments indicate a supposed increase in estradiol concen-
tration during the active pill phase had no effect on the above 
variables. However, in the present work, the estradiol con-
centration during the active pill phase was low. Clearly, this 
cannot preclude that higher estradiol concentrations would 
have no effect. Indeed, the present and other authors' results15 
show that 17 β-estradiol concentrations are lower during the 
active pill phase than during the late withdrawal phase, and 
similar during the early withdrawal phase. In fact, serum hor-
mone concentrations were not measured in the above earlier 
work,14,24 yet the authors concluded that that any downregu-
lation of hepcidin via estradiol in animal models might not 
apply in the typical post-exercise response in humans.
IL-6 production has also been reported inhibited by 
17β-estradiol in vitro25 and in vivo in animals.26 However, 
IL-6 was also previously reported to be unaffected by low 
17 β-estradiol concentrations, in agreement with studies 
showing neither resting IL-624 nor post-exercise IL-614 to be 
affected.
The present time-course results for both hepcidin and IL-6 
after exercise are consistent with those of many other studies 
performed in men and women.13 In the present work, a peak 
in IL-6 concentrations was observed at 0 hour post-exercise, 
while 3  hours later a significant increase in hepcidin was 
F I G U R E  1  A, Serum hepcidin, B, serum IL-6, C, serum TNF-α, and D, serum CRP concentrations (mean ± SEM) in the withdrawal and 
active pill phases at specific times before and after exercise. *Significantly different from pre-exercise. #Significantly different from 0 h post-
exercise. aSignificantly different from withdrawal phase. Abbreviations: Post 0 h, 0 h post-exercise; Post 3 h, 3 h post-exercise; Post 24 h, 24 h 
post-exercise; CRP, C-reactive protein; TNF-⍺, tumor necrosis factor alpha
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seen—a response similar in both the withdrawal and active 
pill phases. Despite the hormonal differences between these 
phases, IL-6 increased after exercise, which may explain the 
lack of difference seen for hepcidin between the two phases.
Significantly higher concentrations of TNF-α were ob-
served during the active pill phase, accompanied with a trend 
toward greater CRP concentrations. This may indicate that, 
during the active pill phase, an inflammatory state is present. 
Several studies have shown that the administration of a phys-
iological dose of estrogen to immature or ovariectomized ro-
dents induces an acute inflammatory-like response.27-29 CRP 
is a well-known general marker of pathological processes 
including infection, tissue damage, cancer, and chronic in-
flammatory disease.30 Further, TNF-α is a proinflammatory 
cytokine involved in the regulation of tissue homeostasis af-
fecting cell proliferation, differentiation, and death.31 It has 
also been reported that serum CRP increases during treatment 
with combined OCs.32 This may be the result of increased 
CRP synthesis by hepatocytes rather than an effect of IL-6- 
or TNF-α-mediated inflammation. In another study,33 a high 
prevalence of low-grade inflammation was detected among 
premenopausal women who used combined OCs, and it was 
therefore suggested that such usage might lead to an elevated 
inflammatory profile. However, none of the aforementioned 
studies compared proinflammatory variables in women with 
different hormonal profiles, or during the different phases 
of a combined OC cycle. Therefore, even though proinflam-
matory markers were higher (or showed a trend toward this) 
in the active pill phase compared to the withdrawal phase, it 
cannot be definitely concluded that the exogenous hormones 
present during the active pill phase induce a stronger inflam-
matory state.
In the present work, TNF-α was elevated at 0 hour post-ex-
ercise in the withdrawal phase. This agrees with the results 
of Peake et al34 who reported a slight increase after similar 
exercise. However, this finding does not necessarily imply 
increased inflammation; the TNF-α concentrations detected 
in the current study may be compatible with a non-inflamma-
tory state since the CRP and IL-6 patterns over time do not 
correspond to inflammation produced by exercise as reported 
in the literature.12
Ferritin also influences plasma hepcidin. Interestingly, 
plasma ferritin before exercise influences the hepcidin re-
sponse 3 hours post-exercise, which becomes stronger the 
higher the pre-exercise ferritin concentration.35 However, 
in the present study, ferritin concentrations were similar in 
both OC phases, as previously reported by Sim et al14 and 
could not, therefore, have unduly influenced the post-ex-
ercise hepcidin response observed in the present subjects. 
However, the present subjects show lower concentrations 
of iron during the withdrawal phase compared to the ac-
tive pill phase, and the opposite with respect to transferrin. 
F I G U R E  2  A, Serum iron, B, serum ferritin, and C, serum transferrin concentrations (mean ± SEM) in the withdrawal and active pill 
phases at specific times before and after exercise. #Significantly different from 0 h post-exercise. aSignificantly different from withdrawal phase. 
Abbreviations: Post 0 h, 0 h post-exercise; Post 3 h, 3 h post-exercise; Post 24 h, 24 h post-exercise; CRP, C-reactive protein; TNF-⍺, tumor 
necrosis factor alpha
650 |   ALFARO-MAGALLANES Et AL.
Transferrin is reduced under inflammation and iron over-
load conditions and increases in iron-deficient situations.36 
Therefore, during the withdrawal phase, the liver may in-
crease circulating transferrin in an attempt to bind more 
iron and thus promote its transport to iron-demanding 
cells. This may be related to the occurrence of menstrual 
bleeding during this phase. Despite menstrual losses being 
smaller in OC cycles than eumenorrheic cycles,37 lower 
plasma iron concentrations are still observed during men-
ses. In addition, the present results showed a trend for hep-
cidin concentrations to be higher at baseline than during 
the withdrawal phase, which along with menstrual bleeding 
may reduce the availability of iron in plasma during that 
phase.
The present work takes into consideration the main hor-
monal fluctuations during an OC cycle via biomarker ver-
ification, as suggested in the literature.38,39 The exercise 
protocol chosen may be similar to a daily training session, 
making results more applicable to the athletes’ day to day. 
Further, the authors excluded women with iron deficiency 
anemia rather than women with iron-depleted stores in order 
to more closely resemble the population of physically active 
women.40 However, the fact that some of the present sub-
jects showed iron depletion in terms of their ferritin status 
(<35  μg/L)40 might have affected the hepcidin response at 
3 hours post-exercise, and have masked the potential effects 
of OC on hepcidin. This potential problem is a concern since 
many active women have low iron stores,40 which could limit 
the response of hepcidin to exercise. Future research should 
examine other variables related to erythropoiesis and hy-
poxia, such as circulating erythropoietin, erythroferrone, and 
hemoglobin levels, among others. Additional measurement 
time points close to and after the hepcidin peak would also 
more accurately record the effects of the hepcidin response 
to exercise on plasma iron. Finally, despite the severity of 
menstrual bleeding being reduced in OC users, the amount of 
blood lost should be examined for a clearer picture of the reg-
ulation of iron homeostasis in this population. Understanding 
these variables would add valuable information on hepcidin 
behavior at rest and in response to exercise in the different 
phases of the OC. Finally, future studies should measure fur-
ther inflammation markers in the different phases of the OC 
cycle.
5 |  CONCLUSION
An interval running exercise performed in the withdrawal 
and active pill phases of a monophasic OC cycle was associ-
ated with similar increases in IL-6 at 0 hour post-exercise, 
and in the size of the consequent peak of hepcidin recorded 
at 3 hours post-exercise. Therefore, a similar iron absorption 
is expectable during the two OC phases after exercise. Low 
endogenous sex hormone concentrations induced by use of 
monophasic OCs do not appear to affect hepcidin.
6 |  PERSPECTIVE
The role of estradiol as a modulator of hepcidin6-8 may offer 
therapeutic advantages in improving iron status. Taking ad-
vantage of estradiol supplementation may help improve iron 
status in female athletes, who commonly have depleted iron 
stores. Earlier research investigating the effect of OC use on 
hepcidin14,24 suggests that any downregulation of the latter 
via estradiol in animal models may not be mirrored in the 
typical post-exercise response in humans. The present study 
shows that OCs do not influence the response of hepcidin to 
exercise—but this is due to the low estradiol concentrations 
seen during OCs consumption, and not to a lack of effect of 
estradiol on hepcidin regulation. Further work should take 
into account hormonal environments with higher estradiol 
concentrations, such as in the eumenorrheic cycle or those 
induced by doses of exogenous hormone supplementation 
higher than those provided by OCs. The latter would help 
elucidate the potential effects of estradiol on hepcidin and its 
response to exercise.
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